Literature DB >> 22233605

Modelling tuberculosis trends in the USA.

A N Hill1, J E Becerra, K G Castro.   

Abstract

We present a mathematical transmission model of tuberculosis in the USA. The model is calibrated to recent trends of declining incidence in the US-born and foreign-born populations and is used in assessing relative impacts of treatment of latently infected individuals on elimination time, where elimination is defined as annual incidence <1 case/million. Provided current control efforts are maintained, elimination in the US-born population can be achieved before the end of this century. However, elimination in the foreign-born population is unlikely in this timeframe even with higher rates of targeted testing and treatment of residents of and immigrants to the USA with latent tuberculosis infection. Cutting transmission of disease as an interim step would shorten the time to elimination in the US-born population but foreign-born rates would remain above the elimination target.

Entities:  

Mesh:

Year:  2012        PMID: 22233605     DOI: 10.1017/S095026881100286X

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  61 in total

1.  Current and future trends in tuberculosis incidence in New York City: a dynamic modelling analysis.

Authors:  Anthony T Fojo; Natalie L Stennis; Andrew S Azman; Emily A Kendall; Sourya Shrestha; Shama D Ahuja; David W Dowdy
Journal:  Lancet Public Health       Date:  2017-07

2.  Changes in Tuberculosis Disparities at a Time of Decreasing Tuberculosis Incidence in the United States, 1994-2016.

Authors:  Awal Khan; Suzanne Marks; Dolly Katz; Sapna Bamrah Morris; Lauren Lambert; Elvin Magee; Sloane Bowman; Gail Grant
Journal:  Am J Public Health       Date:  2018-11       Impact factor: 9.308

Review 3.  Advances in the development of new tuberculosis drugs and treatment regimens.

Authors:  Alimuddin Zumla; Payam Nahid; Stewart T Cole
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

4.  Policy Implications of Mathematical Modeling of Latent Tuberculosis Infection Testing and Treatment Strategies to Accelerate Tuberculosis Elimination.

Authors:  Suzanne M Marks; David W Dowdy; Nicolas A Menzies; Priya B Shete; Joshua A Salomon; Andrea Parriott; Sourya Shrestha; Jennifer Flood; Andrew N Hill
Journal:  Public Health Rep       Date:  2020 Jul/Aug       Impact factor: 2.792

5.  Screening for Latent Tuberculosis Infection Among HIV-Infected Medicaid Enrollees.

Authors:  Eleanor E Friedman; Awal Khan; Wayne A Duffus
Journal:  Public Health Rep       Date:  2018-06-21       Impact factor: 2.792

6.  Tuberculosis among Newly Arrived Immigrants and Refugees in the United States.

Authors:  Yecai Liu; Christina R Phares; Drew L Posey; Susan A Maloney; Kevin P Cain; Michelle S Weinberg; Kristine M Schmit; Nina Marano; Martin S Cetron
Journal:  Ann Am Thorac Soc       Date:  2020-11

Review 7.  The impact of migration on tuberculosis in the United States.

Authors:  N A Menzies; A N Hill; T Cohen; J A Salomon
Journal:  Int J Tuberc Lung Dis       Date:  2018-12-01       Impact factor: 2.373

8.  Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.

Authors:  Robert Belknap; David Holland; Pei-Jean Feng; Joan-Pau Millet; Joan A Caylà; Neil A Martinson; Alicia Wright; Michael P Chen; Ruth N Moro; Nigel A Scott; Bert Arevalo; José M Miró; Margarita E Villarino; Marc Weiner; Andrey S Borisov
Journal:  Ann Intern Med       Date:  2017-11-07       Impact factor: 25.391

9.  Exogenous Reinfection as a Cause of Late Recurrent Tuberculosis in the United States.

Authors:  Julia D Interrante; Maryam B Haddad; Lindsay Kim; Neel R Gandhi
Journal:  Ann Am Thorac Soc       Date:  2015-11

10.  Prospects for Tuberculosis Elimination in the United States: Results of a Transmission Dynamic Model.

Authors:  Nicolas A Menzies; Ted Cohen; Andrew N Hill; Reza Yaesoubi; Kara Galer; Emory Wolf; Suzanne M Marks; Joshua A Salomon
Journal:  Am J Epidemiol       Date:  2018-09-01       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.